Tramadol (Ultram), the alternative, synthetic opioid pain reliever, has seen increasing use since it was first approved by the Food and Drug Administration (FDA) in 1994. However, a decision by the Drug Enforcement Administration (DEA) to list tramadol as a Schedule IV controlled substance (Aug. 2014) may mean changes for how the drug is prescribed.
To continue reading this article or issue you must be a paid subscriber
Subscribe to Arthritis Advisor
Get the next year of Arthritis Advisor for just $20. And access all of our online content - over 1,000 articles - free of charge.
Subscribe today and save 36%. It's like getting 4 months FREE!
Already Subscribed?
Click Here to Sign In |
Forgot your password? |
Activate Web Access
